Malignant neoplasm of breastpredictiveEstrogen ReceptorsBiological Markers生物学标记Optimal selection of endocrine therapy for women with estrogen receptor-positive breast cancer will require biomarkerswith better positive predictive value than the current immunohistochemical assay. There has been great interest ...
Genomic testing in early-stage hormone-positive breast cancer is the standard of care. However, decisions based on genomic testing results are predicated on the assumption that patients receive endocrine treatment. We sought to investigate racial differences in genomic testing and adjuvant treatment in ...
A discussion on clinical considerations for genomic testing in patients with early-stage breast cancer.
Based on genomic testing studies, we know that there are different molecular subtypes of cancer. One woman’s breast cancer may be quite different from another’s; each type has its own prognosis and requires its own medical treatment. Many cases of invasive breast cancer are less biologically...
"As clinical genetic testing becomes more widely accessible, we undoubtedly will see a rise in the incidence of PHTS-associated breast cancer," said Charis Eng, MD, Ph.D., Chair of the Genomic Medicine Institute and the study's corresponding author. "PHTS-associated breast cancers often devel...
The implementation of cancer genomic testing into the clinical setting has brought major opportunities. However, as our understanding of cancer initiation,... Andre,F. (AUTHOR),Mardis,... - 《Annals of Oncology》 被引量: 70发表: 2014年 On the Road to Precision Cancer Medicine: Analysis of ...
However, genomic testing revealed that response rates were much higher in those without a KRAS mutation in their tumor [3]. Other examples are HER2 expression in breast cancer patients, which predicts response to trastuzumab [4] and the BCR-ABL genotype in chronic myeloid leukemia, which ...
breast cancer patients. A total of 71 studies were analyzed, including 561,188 patients of whom 27,748 (4.9%) were young. Women aged ≤40 years were subjected to genomic testing at a similar rate to older women but had a higher proportion of intermediate- to high-risk tumors when ...
C. Liedtke, H.-C. Kolberg First published:16 March 2017 https://doi.org/10.1002/bjs.10513 Citations:2 Read thefull text PDF Tools Share Abstract Makes a real difference References Citing Literature Volume104,Issue7 June 2017 Pages799-801 ...
When considering the full set of 506 breast cancer samples, four SNP loci with significant DI, i.e. higher relative expression of the silenced allele, could be identified (FDR ≤ 0.1; Table2). These SNPs correspond to three genes, namelyMEST,H19andHM13. Figure2shows the mixture distribut...